BioMed Research International

Adverse Reactions to Anticancer Drugs in the Oral Cavity

Publishing date
01 Jul 2018
Submission deadline
02 Mar 2018

Lead Editor

1University of Palermo, Palermo, Italy

2University College London, London, UK

3Tel Aviv University, Tel Aviv, Israel

4Valencia University, Valencia, Spain

5Ludwig-Maximilians-University of Munich, Munich, Germany

Adverse Reactions to Anticancer Drugs in the Oral Cavity


In the last year, new drugs of the anticancer therapeutic protocols are focused on by clinicians, in order to monitor and prevent also potential adverse effects, from stomatitis to MRONJ. Targeted therapies and the new biologic agents have revolutionized the treatment of cancers, autoimmune diseases, and inflammatory and rheumatologic diseases but could be also responsible for severe and discouraging oral diseases. In particular, OsteoNecrosis of the Jaw (ONJ) represents a harsh and devastating condition that firstly appeared as a bisphosphonate- (BP-) related class effect. Later, many studies have shown that the new receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab can equally induce ONJ. Recently, ONJ cases are reported after treatment including antiangiogenic agents and other “targeted therapy,” with and without BPs, in cancer patients, determining the new term introduced in medical literature, called Medication-Related OsteoNecrosis of Jaw (MRONJ).

The special issue aims at presenting current knowledge on the most severe disease related to anticancer therapy, describing the most common clinical presentations of oral reactions to anticancer drugs, describing the pathway of differential diagnosis of oral reactions to anticancer drugs, and focusing on the state of the art on medical protocols for managing oral adverse reactions.

Potential topics include but are not limited to the following:

  • Oral adverse events
  • Osteonecrosis of the jaw
  • Mucositis
  • New drugs of anticancer therapy
  • Quality of life of patients with adverse drug events


  • Special Issue
  • - Volume 2018
  • - Article ID 1372874
  • - Editorial

Adverse Reactions to Anticancer Drugs in the Oral Cavity

Olga Di Fede | Noam Yarom | ... | Stefano Fedele
  • Special Issue
  • - Volume 2018
  • - Article ID 2684924
  • - Review Article

The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention

Olga Di Fede | Vera Panzarella | ... | Giuseppina Campisi
  • Special Issue
  • - Volume 2018
  • - Article ID 3982540
  • - Clinical Study

Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study

Rodolfo Mauceri | Vera Panzarella | ... | Giuseppina Campisi
  • Special Issue
  • - Volume 2018
  • - Article ID 9858921
  • - Review Article

Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review

Roberto Sacco | Nicola Sacco | ... | John St. J. Blythe
  • Special Issue
  • - Volume 2018
  • - Article ID 5035217
  • - Review Article

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Claudia Arena | Giuseppe Troiano | ... | Lorenzo Lo Muzio
  • Special Issue
  • - Volume 2018
  • - Article ID 8071579
  • - Review Article

Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature

Kununya Pimolbutr | Stephen Porter | Stefano Fedele
BioMed Research International
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision128 days
Acceptance to publication21 days
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.